| Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury. | |
| | |
MedLine Citation:
|
PMID: 11966529 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: A recent study demonstrated that inhibition of both cyclooxygenase (COX)-1 and COX-2 is required for the development of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric lesions. However, the role of COX-1 or COX-2 inhibition in the pathogenisis of these lesions remains unclear. AIM: To examine the gastric ulcerogenic properties of selective COX-1 and COX-2 inhibitors in rats and to investigate further the relationship of COX inhibition to various events involved in the process of NSAID-induced gastric lesions. METHODS: Animals were given various COX inhibitors p.o., either alone or in combination, and killed 8 h later. Under the treatment, gastric damage, prostaglandin (PG) E2 content, mucosal permeability, myeloperoxidase (MPO) activity as well as gastric motility were examined. RESULTS: The nonselective COX inhibitor indomethacin inhibited PGE2 production, enhanced gastric motility, and provoked severe lesions in the stomach, with an increase in mucosal permeability and MPO activity. In contrast, the selective COX-2 inhibitor rofecoxib did not induce any damage in the stomach and had no effect on mucosal PGE2 content. Similarly, the selective COX-1 inhibitor SC-560 also caused no gastric damage, despite inhibiting PGE2 production. The combined administration of SC-560 and rofecoxib, however, provoked gross damage in the gastric mucosa, in a dose-dependent manner for each drug. SC-560, but not rofecoxib, caused marked gastric hypermotility and an increase in mucosal permeability, although an increase in MPO activity was observed only when rofecoxib was coadministered. The normal gastric mucosa expressed COX-1 mRNA and not COX-2 mRNA, but COX-2 mRNA was expressed in the stomach after administration of SC-560 as well as indomethacin but not rofecoxib. CONCLUSION: These results suggest that the gastric ulcerogenic properties of NSAIDs are not accounted for solely by COX-1 inhibition, but require the inhibition of both COX-1 and COX-2. The inhibition of COX-1 up- regulates COX-2 expression, and COX-2/PGs may, in turn, counteract the deleterious affects of gastric hypermotility due to COX-1 inhibition. |
| | |
Authors:
|
A Tanaka; H Araki; S Hase; Y Komoike; K Takeuchi |
Related Documents
:
|
14724349 - The gastroprotective effect of tannins extracted from duhat (syzygium cumini skeels) ba... 19038699 - Gastroprotective effect of cyanidin 3-glucoside on ethanol-induced gastric lesions in r... 8626049 - Adaptive gastric mucosal cytoprotection in rats: different modes of action by three mil... 3464999 - Effect of sofalcone on gastric mucosal prostaglandin metabolism in taurocholate induced... 1742209 - A fall in duodenal pge2 synthesis precedes histological changes and ulceration in the c... 20012499 - Suppression of hypothalamo-hypophyseal-adrenocortical system function as the cause of a... 2463039 - The iminodipropionitrile (idpn) model of persistent spasmodic dyskinesias: regional ser... 15932609 - Recognition memory impairment and brain oxidative stress induced by postnatal iron admi... 6259669 - Effects of body weight levels on cannabis self-injection. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 16 Suppl 2 ISSN: 0269-2813 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 2002 Apr |
Date Detail:
|
Created Date: 2002-04-22 Completed Date: 2002-07-15 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 90-101 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology & Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amino Acid Sequence Animals Anti-Inflammatory Agents, Non-Steroidal / pharmacology* Cyclooxygenase 1 Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors / pharmacology* Dinoprostone / biosynthesis Gastrointestinal Hemorrhage / etiology, physiopathology Gastrointestinal Motility / drug effects Gene Expression Indomethacin / pharmacology Isoenzymes / antagonists & inhibitors*, biosynthesis*, genetics Lactones / pharmacology Male Membrane Proteins Molecular Sequence Data Prostaglandin-Endoperoxide Synthases / biosynthesis*, genetics RNA, Messenger / analysis Rats Rats, Sprague-Dawley Stomach Ulcer / chemically induced, complications, physiopathology Sulfones Up-Regulation |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors; 0/Cyclooxygenase Inhibitors; 0/Isoenzymes; 0/Lactones; 0/Membrane Proteins; 0/RNA, Messenger; 0/Sulfones; 0/rofecoxib; 363-24-6/Dinoprostone; 53-86-1/Indomethacin; EC 1.14.99.1/Cyclooxygenase 1; EC 1.14.99.1/Cyclooxygenase 2; EC 1.14.99.1/Prostaglandin-Endoperoxide Synthases; EC 1.14.99.1/Ptgs1 protein, rat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibition of proliferation of gastric epithelial cells by a cyclooxygenase 2 inhibitor, JTE522, is ...
Next Document: Review article: COX-2, prostanoids and colon cancer.